Table 1.

Selected baseline characteristics of users and nonuser sub-cohorts.

Characteristics	Users of AChEIs (n = 223)	Nonusers (n=309)	P-value b
Age in years
Mean ± SD	84.0 ± 7.0	84.6 ± 6.4	0.25
Sex
Men	21.5	26.2	0.21
Women	78.5	73.8
Years in the GPRD
Mean ± SD	5.5 ± 4.4	6.1 ± 4.0	0.07
Median (IQR)	3.6 (1.7 - 9.4)	5.5 (2.5 - 9.0)	0.02
Smoking status
Never	51.6	50.2
Current	1.8	1.9	0.93
Ex-smoker	4.9	5.5
Missing	41.7	42.4
Body mass index a
<20	16.6	17.5
20-24	29.2	33.0
25-29	12.1	14.2	0.59
≥30	4.0	2.9
Unknown	38.1	32.4
Duration of Alzheimer disease
<2	47.1	35.9
2-6	46.6	54.1	0.02
≥6	6.3	10.0
Surgical treatment
Joint replacement	56.5	45.0	0.009
Osteosynthesis	43.5	55.0
Comorbidity factors
Chronic pulmonary disease	14.4	18.5	0.21
Diabetes	9.4	6.5	0.21
Cerebrovascular disease	9.9	13.9	0.16
Chronic liver disease	0.5	0.3	0.49
Ischemic heart disease	83.0	86.1	0.32
Peptic ulcer	5.4	10.0	0.05
Renal diseases	2.2	3.2	0.49
Known Osteoporosis	3.1	2.6	0.71
History of falls	37.7	42.1	0.31
Institutionalization	21.1	12.3	0.006
Mobility
Walks without aid	93.7	95.2
Poor mobility	2.2	3.2
Very Poor mobility	0.3	0.9	0.34
Use of wheelchair	0.0	0.0
Bedridden	3.1	1.3
Use of medication
PPI	21.5	18.8	0.43
Statins	19.3	12.3	0.02
SSRI	25.6	20.4	0.16
Hypnotics	39.5	38.8	0.88
Diuretics	13.5	15.5	0.50
ACE inhibitors	17.5	10.4	0.02
Pre-baseline use of AChEIs	91.3	40.8	<0.001

Abbreviations: CI, confidence interval, PPI-proton pump inhibitors; SSRI- selective serotonin reuptake; ACE-Angiotensin converting enzyme, AChEIs - acetylcholinesterase inhibitors.

^aMeasured as weight in kilograms divided by the square of height in meters*.

^bNonparametric median test and Chi2 test for homogeneity.